Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026
Rhea-AI Summary
Relmada Therapeutics (Nasdaq: RLMD) will report first quarter 2026 financial results and host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET. The company will discuss results for the quarter ended March 31, 2026 and provide updates on recent business and clinical progress.
Participant dial-in numbers and a webcast link are provided; a replay will be available in the Investors section of the Relmada website.
Positive
- None.
Negative
- None.
News Market Reaction – RLMD
On the day this news was published, RLMD gained 6.94%, reflecting a notable positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $54M to the company's valuation, bringing the market cap to $837.02M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings date notice | Neutral | -2.7% | Announcement of Q4 2025 results date and related conference call details. |
| Nov 07 | Earnings date notice | Neutral | +1.5% | Scheduling of Q3 2025 results release and investor conference call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior earnings date notices for RLMD led to modest moves of -2.69% and +1.53%, with no clear directional bias.
Over recent months, Relmada has used earnings date press releases to signal upcoming financial and business updates via conference calls and webcasts. Prior earnings date announcements on Nov 07, 2025 and Mar 12, 2026 preceded moves of +1.53% and -2.69%, respectively, indicating historically small reactions to this type of scheduling news. Today’s notice continues that pattern by setting expectations for when first quarter 2026 results and recent progress will be discussed.
Key Terms
central nervous system medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Tuesday, May 12, 2026 at 4:30 PM ET to discuss financial results for the first quarter ended March 31, 2026, and recent business progress.
Conference Call and Webcast Information:
- Date: Tuesday, May 12, 2026 at 4:30 PM ET
- Participant Dial-in (US): 1-800-717-1738
- Participant Dial-in (International): 1-646-307-1865
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
